Wuxi Biologics. WuXi AppTec. Porton Pharma. These names are not yet household words in Western boardrooms — but they are reshaping where the world’s medicines are made, tested, and shipped. China’s contract development and manufacturing organization (CDMO) sector has grown from a niche of low-cost generics copiers into a $30-billion-plus global business that handles formulation, clinical trial materials, and commercial-scale biologics production for some of the largest pharmaceutical companies on earth.
For Western life sciences executives, understanding China’s CDMO boom is no longer optional. It is a supply chain, cost, and strategic imperative.
What Is a CDMO and Why Does It Matter?
A contract development and manufacturing organization handles the outsourced research, development, scale-up, and production of pharmaceutical ingredients and finished drug products. Instead of building billion-dollar facilities in-house, biotech startups and large pharma companies contract out this work to CDMOs for speed, capital efficiency, and technical expertise.
Global pharmaceutical outsourcing was already a $200 billion market before COVID-19. The pandemic accelerated it dramatically, as vaccine manufacturers scrambled for fill-and-finish capacity worldwide. China’s CDMOs were ideally positioned: government-backed, well-capitalized, and operating under increasingly rigorous quality standards aligned with U.S. FDA and European EMA requirements.
Wuxi Biologics: The Company That Defined the Sector
No story about China’s CDMO rise is complete without Wuxi Biologics. Founded in 2010 and listed on the Hong Kong Stock Exchange in 2017, Wuxi Biologics generated revenue of approximately RMB 10.3 billion (about $1.4 billion USD) in fiscal year 2023. The company operates more than 30 manufacturing sites across China, Ireland, Germany, Singapore, and the United States, with combined bioreactor capacity exceeding 340,000 liters.
Its business model is called “follow the molecule”: Wuxi Biologics signs on at the earliest pre-clinical stage, providing cell line development, process development, and clinical manufacturing, then scales with the client all the way to commercial production. By embedding deep in early-stage development, the company creates long-term customer relationships that are structurally difficult to exit. As of 2024, its pipeline included over 700 projects globally.
The parent ecosystem, WuXi AppTec, operates across drug discovery, testing, and manufacturing. WuXi AppTec reported 2023 revenues of approximately RMB 40 billion ($5.5 billion USD), with operations spanning over 30 countries and a client list that includes 9 of the world’s top 10 pharmaceutical companies.
The Other Major Players: Porton, Asymchem, and STA Pharmaceutical
The WuXi group dominates headlines, but the sector has depth. Porton Pharma Solutions has evolved from state-owned roots into a leading small-molecule API (active pharmaceutical ingredient) platform operating major sites in Chongqing and Hunan, with European expansion through acquisition of Hovione’s CDMO assets.
Asymchem Laboratories, listed on China’s STAR Market, is among the most technically sophisticated operators in continuous flow chemistry — a manufacturing method that reduces batch variability and improves safety profiles for complex molecules. Its client base is predominantly Western biotech and generics manufacturers seeking FDA-compliant manufacturing at competitive cost.
STA Pharmaceutical, a WuXi AppTec subsidiary, specializes in oligonucleotides and highly potent API synthesis — including GLP-1 receptor agonist peptides, the class of molecules behind blockbuster weight-loss drugs like semaglutide and tirzepatide. As global demand for these medications surged in 2023 and 2024, STA’s Changzhou facilities were operating near full capacity serving global pharmaceutical clients.
Government Policy and the CDMO Industrial Cluster
China’s CDMO success is not purely market-driven. The central government has designated pharmaceutical manufacturing as a strategic industry under the Made in China 2025 framework. Wuxi in Jiangsu province, Chengdu in Sichuan, and the Yangtze River Delta corridor have been developed as designated pharmaceutical industrial parks with preferential land, tax, and R&D incentive policies.
The National Medical Products Administration (NMPA) has undertaken a sustained quality upgrade program, aligning Chinese GMP (Good Manufacturing Practice) standards more closely with ICH (International Council for Harmonisation) guidelines. This regulatory convergence is critical: without credible FDA and EMA acceptance of Chinese facility inspections, Western pharma companies could not rely on Chinese CDMOs for regulated commercial supply. As of 2024, dozens of Chinese CDMO manufacturing sites hold active U.S. FDA establishment registrations — a qualitative shift from five years earlier.
The BIOSECURE Act and Geopolitical Risk
The geopolitical dimension cannot be ignored. In 2024, the U.S. Congress introduced the BIOSECURE Act, legislation that would prohibit federal contractors from using services from named Chinese biotech companies — including WuXi AppTec and Wuxi Biologics — on national security grounds. The bill’s rationale: Chinese CDMOs handling sensitive biological data from American drug development could expose proprietary research to Chinese government access under China’s national security law framework.
The legislation sent shockwaves through Western biotech. Companies that had structured their entire development pipeline around WuXi platforms suddenly faced mandatory re-sourcing. U.S. and European CDMOs — Lonza, Samsung Biologics, and Thermo Fisher Scientific — reported surges in inbound inquiries and capacity bookings.
Yet the practical reality is complex. Switching CDMOs is not like switching commodity suppliers. A company that has used Wuxi Biologics for cell line development, process development, and Phase I/II clinical manufacturing over three years cannot simply transfer that institutional knowledge to a new vendor in six months. Re-sourcing at commercial scale requires facility qualification, regulatory filing updates, and potentially new clinical data — a process costing tens of millions per program.
As of mid-2026, the BIOSECURE Act’s most restrictive provisions have been debated but not fully enacted. Most industry analysts expect a phased wind-down rather than an abrupt cutoff, with new programs directed toward non-Chinese alternatives while legacy work completes.
A Practical Framework for Western Executives
The CDMO landscape is shifting, but Chinese contract manufacturers retain real cost and capability advantages. Here is a practical framework for navigating the environment:
Audit Your Exposure
Map every program to its CDMO relationships. Identify which are China-based, at what clinical stage, and what regulatory filings name which facilities. This inventory is the foundation of any risk management plan and is increasingly required in M&A due diligence.
Separate API From Finished Drug Product
For many programs, the API can be manufactured in China while finished drug product filling and packaging is done in a Western or Korean facility. This hybrid model preserves cost advantages while reducing geopolitical exposure at the most sensitive — and most visible — stage of the supply chain.
Build Dual-Source Capability for Commercial Programs
For any drug approaching commercial approval, qualifying a second manufacturing site is now standard practice. The incremental cost is real, but the supply security benefit is substantial, as COVID-era API shortages demonstrated. The U.S. FDA’s guidance on supply chain resilience explicitly recommends dual-source qualification for critical drug products.
The Bigger Picture
The CDMO story is one piece of a larger transformation. China is simultaneously the world’s largest producer of pharmaceutical active ingredients, a growing force in generic drug manufacturing, and an increasingly serious developer of innovative biologics and small molecules. For broader context on this transformation, see our coverage of China’s Pharmaceutical Industry: How Generic Manufacturing and Biotech Innovation Are Reshaping Global Healthcare. For the medical technology side, our analysis of Mindray, BGI, and United Imaging: How China’s MedTech Champions Are Going Global provides essential context. For the broader supply chain risk picture, US-China Supply Chain Guide: Managing Risk, Building Resilience, and Staying Competitive offers a comprehensive framework. The device sector context is available in our piece on China’s Medical Device Industry: How It Became a Global Force.
The US Food and Drug Administration publishes guidance on foreign drug manufacturing facility inspections and CDMO compliance at fda.gov/drugs/pharmaceutical-quality-resources.
The decisions Western drug companies make about where to manufacture over the next three to five years will shape patient access, drug pricing, and national health security for decades. Understanding what China’s CDMO sector actually is — its capabilities, costs, risks, and regulatory standing — is the essential starting point for getting those decisions right.